Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. Oppenheimer & Co. Inc. and Citizens JMP are acting as joint book-running managers for the offering. Stephens Inc. is acting as lead manager for the offering.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INO:
- Inovio’s INO-3107 shows efficacy in Phase 1/2 RRP trial
- Inovio price target lowered to $15 from $33 at Oppenheimer
- Inovio price target lowered to $5 from $12 at H.C. Wainwright
- Inovio Pharmaceuticals Advances DNA Medicine Development
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
